TABLE 7.
Genotype distribution and comparison results with the allele frequency of the study population in the dose research group.
| SNP Id | Observation subgroup n = 50 (%) | Control subgroup n = 50 (%) | χ2 | P-value | OR (95% CI) |
|---|---|---|---|---|---|
| CYP2D6*10 (rs1065852, C>T) | |||||
| CC | 25 (50.00) | 22 (44.00) | |||
| CT | 18 (36.00) | 20 (40.00) | |||
| TT | 7 (14.00) | 8 (16.00) | |||
| CT + TT | 25 (50.00) | 28 (56.00) | 0.475 | 0.924* | 1.075 (0.833–1.386) |
| Allelic | |||||
| C | 68 (68.00) | 64 (64.00) | |||
| T | 32 (32.00) | 36 (36.00) | 0.357 | 0.55 | 1.195 (0.665–2.147) |
| OPRM1 (rs1799971, A>G) | |||||
| AA | 30 (60.00) | 26 (52.00) | |||
| AG | 15 (30.00) | 17 (34.00) | |||
| GG | 5 (10.00) | 7 (14.00) | |||
| AG + GG | 20 (40.00) | 24 (48.00) | 0.997 | 0.802* | 1.118 (0.862–1.449) |
| Allelic | |||||
| A | 75 (75.00) | 69 (69.00) | |||
| G | 25 (25.00) | 31 (31.00) | 0.627 | 0.428 | 1.286 (0.690–2.397) |
| ABCB1(rs1045642, C>T) | |||||
| CC | 25 (50.00) | 20 (40.00) | |||
| CT | 20 (40.00) | 15 (30.00) | |||
| TT | 5 (10.00) | 15 (30.00) | |||
| CC + CT | 45 (90.00) | 35 (70.00) | 6.986 | 0.072* | 1.018 (0.806–1.285) |
| Allelic | |||||
| C | 70 (70.00) | 55 (55.00) | |||
| T | 30 (30.00) | 45 (45.00) | 3.125 | 0.077 | 1.690 (0.943–3.029) |
| CYP3A5*3 (rs776746, A>G) | |||||
| AA | 8 (16.00) | 9 (18.00) | |||
| AG | 16 (32.00) | 17 (34.00) | |||
| GG | 26 (52.00) | 24 (48.00) | |||
| AG + GG | 42 (42.00) | 41 (41.00) | 0.176 | 0.981* | 0.958 (0.717–1.281) |
| Allelic | |||||
| A | 32 (32.00) | 35 (35.00) | |||
| G | 68 (68.00) | 65 (65.00) | 0.202 | 0.653 | 0.874 (0.486–1.573) |
Note: * indicates calculations based on the following genotype group comparisons: CT + TT vs CC, AG + GG vs AA, and CC + CT vs TT.